May 22, 2013

May 21, 2013

May 19, 2013

May 16, 2013

  • Injectable nanoparticles developed at Massachusetts Institute of Technology (MIT) may someday eliminate the need for patients with Type 1 diabetes to constantly monitor their blood-sugar levels and inject themselves with insulin. The nanoparticles were designed to sense glucose levels in the body and respond by secreting the appropriate amount of insulin, thereby replacing the function of pancreatic islet cells, which are destroyed in patients with Type 1 diabetes.
  • AstraZenecaAstraZeneca today announced that it will be moving three of its cancer compounds forward to Phase III clinical development. As set out at its Investor Day in March, oncology is one of the company's core therapy areas and accelerating the development of a number of new molecular entities in its pipeline is a strategic priority.

May 15, 2013

May 14, 2013

May 13, 2013

May 12, 2013

May 10, 2013

Need help?

Feeds shows the latest news items retrieved from the site's feeds. You can switch the display between articles, condensed list, and map display modes using the icons at the top right.

Embed
Copy and paste this code to your website.
User login
11:06pm May 24+2:00 GMT